News & Updates

Neoadjuvant chemohormonal therapy (NCHT) plus radical prostatectomy (RP) confers significant biochemical progression-free survival (bPFS) benefits relative to neoadjuvant hormonal therapy (NHT) plus RP on patients with high-risk, locally advanced prostate cancer, reports a study.

Patient-reported outcomes (PROs) from the phase III MIRASOL trial underpin the potential of the antibody drug conjugate mirvetuximab soravtansine (MIRV) to improve health-related quality of life (HRQoL) in women with folate receptor-alpha positive platinum-resistant ovarian cancer (FRα-positive PROC) as opposed to investigator’s choice of chemotherapy.

Patients with type 2 diabetes (T2D) who received combined treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have a much lower risk of major adverse cardiovascular events (MACE) and serious renal events than those treated with either drug class alone, suggests a recent study.

The weight loss and heart failure (HF) benefits of semaglutide extend to patients with obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D) in the STEP-HFpEF DM trial, fuelling speculation that semaglutide may have cardiovascular effects beyond weight loss.

Taking aspirin in the adjuvant setting does not appear to lower the risk of recurrence or improve survival in patients with high-risk nonmetastatic breast cancer, as shown in the results of the phase III Alliance A011502 trial.